Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1611 to 1620 of 1911 total matches.
Doripenem (Doribax) - A New Parenteral Carbapenem
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008 (Issue 1278)
adjustment may be necessary in patients with renal or hepatic
dysfunction.
2. Cost of one day’s treatment ...
Doripenem (Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of complicated intra-abdominal and urinary tract infections. Use of doripenem for treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is still under FDA review.
Deep Brain Stimulation for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009 (Issue 1309)
PD (mean disease duration 12.4 years). Patients who received DBS
gained a mean of 4.6 hours/day ...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Drugs for Hypertriglyceridemia
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013 (Issue 1411)
1. Wholesale acquisition cost (WAC) of 30 days’ treatment with the highest recommended usual adult ...
Fibrates, niacin and fish oil are promoted for treatment
of hypertriglyceridemia. HMG-CoA reductase inhibitors
(statins) can lower elevated serum concentrations of
triglycerides, but less so than fibrates, niacins or fish oil.
Lifestyle changes such as weight reduction, exercise
and decreasing alcohol intake can also lower serum
triglyceride levels and should be tried first.
Fluticasone Furoate (Arnuity Ellipta) for Asthma
The Medical Letter on Drugs and Therapeutics • May 25, 2015 (Issue 1469)
dosing instructions.
2. Approximate WAC for 30 days’ treatment at the lowest usual adult dosage. WAC ...
The FDA has approved Arnuity Ellipta (GSK), a single-agent
inhaler containing the corticosteroid fluticasone
furoate, for once-daily maintenance treatment of
asthma in patients ≥12 years old. Fluticasone furoate
is also available in combination with the long-acting
beta2-agonist vilanterol as Breo Ellipta for treatment
of asthma and COPD.
Ocrelizumab (Ocrevus) for MS
The Medical Letter on Drugs and Therapeutics • Jun 19, 2017 (Issue 1523)
every lymphopenia with interferon beta-1b
Betaseron (Bayer) other day 86,895.70
Extavia (Novartis ...
The FDA has approved ocrelizumab (Ocrevus –
Genentech), a humanized anti-CD20 monoclonal
antibody, for treatment of adults with primary
progressive or relapsing multiple sclerosis (MS). It is the
first anti-CD20 monoclonal antibody to be approved for
treatment of MS and the first disease-modifying drug
to be approved in the US for primary progressive MS.
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
the 30 days after vaccination.
PREGNANCY AND LACTATION — Penbraya has not
been studied in pregnant ...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 doi:10.58347/tml.2024.1698b | Show Introduction Hide Introduction
Prenatal Acetaminophen Use and Autism
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025 (Issue 1743)
pregnancy (def ned as ≥2 days/week before 1995
and ≥1 day/week afterwards) was associated ...
Acetaminophen has been considered the drug
of choice for treatment of fever and pain during
pregnancy for decades, but a recent announcement
by the US Department of Health and Human Services
(HHS) has prompted discussion about its effects on
fetal neurodevelopment and the risk of autism.
Med Lett Drugs Ther. 2025 Dec 8;67(1743):193-5 doi:10.58347/tml.2025.1743a | Show Introduction Hide Introduction
Drugs for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025 (Issue 1719)
) $2100.00
Pegcetacoplan – 15 mg/0.1 mL q25-60 days
Syfovre (Apellis) 2190.00
1. A topical microbicide ...
Age-related macular degeneration (AMD) has two
major forms: dry or non-neovascular (~90% of
patients) and wet or neovascular (~10% of patients).
Med Lett Drugs Ther. 2025 Jan 6;67(1719):1-5 doi:10.58347/tml.2025.1719a | Show Introduction Hide Introduction
Treatment of Xerostomia
The Medical Letter on Drugs and Therapeutics • Jul 29, 1988 (Issue 771)
agonist pilocarpine, 5 mg to 30 mg, divided into one to four
oral doses per day, has been reported ...
Xerostomia, dry mouth due to decreased or absent saliva, is a common problem, particularly among elderly patients. Decreased salivary flow can be due to many different conditions, including drug therapy, Sj gren's syndrome (keratoconjunctivitis sicca) or radiation of the salivary glands.
The Cervical Cap
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
for several days.
CONCLUSION — The Prentif cervical cap is about as effective as a diaphragm, but remains ...
The US Food and Drug Administration recently approved the marketing of a cervical cap (Prentif Cavity-Rim Cervical Cap - Lamberts Ltd, England), a contraceptive device that has been used in one form or another for many years (JP Koch, Contraception, 25:161, 1982). The cap is being distributed in the USA and Canada by Cervical Cap (CxC), Ltd, PO Box 38003-292, Los Gatos, CA 95031, telephone 408-358-6264; the distributor will make the caps available only to practitioners who have attended training seminars.
